In vitro studies have shown that BDNF exerts beneficial effects on the liver by promoting β-oxidation of free fatty acids and inhibiting gluconeogenesis through AMPK activation in mouse hepatocytes [111], whereas in cirrhosis, hyperammonemia has been demonstrated to activate NF-κB in skeletal muscle, leading to increased myostatin expression [107]. Here, MSTN is linked to Hyperammonemia.